IntroductionCervical cancer is the third most frequent type of cancer in women worldwide, including 529,828 new cases and 275,128 deaths in 2008, of which 31,712 occurred in Latin America and the Caribbean. A total of 85% of new cases take place in developing countries. The standard incidence rate by age in South America is 24.1 cases/100,000 women. In Paraguay, the incidence and mortality rates are 35.0 and 16.6/100,000 women, respectively. These rates are significantly higher than those recorded in neighboring countries such as Argentina, Brazil, Uruguay and Chile 1 . The human papillomavirus (HPV) is a factor involved in the development of cervical cancer. There are more than 100 types of HPV, of which approximately 40 infect the anogenital mucosa. These are categorized into high-risk viruses (HR-HPV) and low--risk viruses (LR-HPV), according to their oncogenic potential, and the HR-HPV (16,18,31,33,35,39, 45, 51, 52, 56, 58, 59, and 66) account for 95% of all cervical cancer cases [2][3][4][5] . The cytological diagnosis (Papanicolaou test) is a simple low-cost method used to detect the cytopathic effect of this virus, although not determining the viral type. As the HPV does not grow in traditional cell cultures, molecular methods have been recently used to identify the viral genotype, such as the Hybrid Capture II® test (HC-II®), which detects 13 types of HR-HPV and enables the viral load to be estimated 6,7 . There are no treatments that can eliminate an HPV-related infection, they can only remove the lesions produced by this virus. The methods used for this treatment are as follows: Loop Electrosurgical Excision Procedure (LEEP), cryotherapy and cervical conization. Although HPVrelated intraepithelial lesions can be treated, there is a chance of recurrence or even the development of cervical cancer. If the lesion extends to the endocervical surgical margin, the risk of failure is higher. Moreover, women who have lesion-free surgical margins show a risk of treatment failure of 2-6%, regardless of the treatment used. The cumulative rate of invasion eight years after treatment is 5.8 cases/1,000 women, which is five times higher than that of the general population [8][9][10][11][12][13][14] . In addition to considering the compromised surgical margins as a recurrence factor, there are other factors that promote the persistence or recurrence of squamous intraepithelial lesions (SIL) after treatment, such as age, parity, cytological diagnosis and degree of lesion prior to treatment 15 . As a result, a continuous and thorough follow-up is important after the treatment. Recent studies suggest that the combined use of cytology and the HC-II® test increases effectiveness when selecting women at risk of developing residual or recurrent SIL after six months of treatment [16][17][18][19] . In Paraguay, previous studies have observed a high frequency of HR-HPV in women without cervical lesions and cofactors of risk (a high number of sexual partners and multiparity, among others) associated with the development of cerv...